Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) and Pulse Biosciences (NASDAQ:PLSE – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for Senseonics Holdings, Inc. Common Stock and Pulse Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senseonics Holdings, Inc. Common Stock | 1 | 1 | 4 | 0 | 2.50 |
| Pulse Biosciences | 1 | 0 | 5 | 1 | 2.86 |
Senseonics Holdings, Inc. Common Stock currently has a consensus target price of $17.20, suggesting a potential upside of 67.35%. Pulse Biosciences has a consensus target price of $50.20, suggesting a potential downside of 2.75%. Given Senseonics Holdings, Inc. Common Stock’s higher probable upside, equities research analysts plainly believe Senseonics Holdings, Inc. Common Stock is more favorable than Pulse Biosciences.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Senseonics Holdings, Inc. Common Stock | -225.09% | -165.80% | -80.14% |
| Pulse Biosciences | -6,755.78% | -94.42% | -79.96% |
Insider and Institutional Ownership
12.4% of Senseonics Holdings, Inc. Common Stock shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 4.7% of Senseonics Holdings, Inc. Common Stock shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Senseonics Holdings, Inc. Common Stock and Pulse Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senseonics Holdings, Inc. Common Stock | $35.26 million | 12.18 | -$69.11 million | ($2.23) | -4.61 |
| Pulse Biosciences | $350,000.00 | 10,441.79 | -$72.78 million | ($1.18) | -43.74 |
Senseonics Holdings, Inc. Common Stock has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Senseonics Holdings, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Senseonics Holdings, Inc. Common Stock has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
Summary
Pulse Biosciences beats Senseonics Holdings, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company’s products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Receive News & Ratings for Senseonics Holdings Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
